Adjuvant chemotherapy following radical cystectomy

Area of Science:

• Uro-oncology
• Medical oncology
• Surgical oncology

Background:

• Optimal management for invasive bladder cancer is debated.
• Adjuvant chemotherapy is considered post-surgery to eradicate micrometastases and reduce recurrence.
• Adjuvant therapy is chemotherapy given after radical cystectomy or aggressive transurethral resection (TUR).

Purpose of the Study:

• To review the current evidence and controversies surrounding adjuvant chemotherapy for invasive bladder cancer.
• To evaluate the potential benefits of adjuvant chemotherapy based on pathologic stage.
• To highlight the challenges in conducting clinical trials for adjuvant therapy in bladder cancer.

Main Methods:

• Review of existing studies and clinical trial data on adjuvant chemotherapy for invasive bladder cancer.
• Analysis of relapse rates per pathologic stage (pT2, pT3a, pT3b, pT4, pN+).
• Discussion of the complexities in designing and executing clinical trials in this patient population.

Main Results:

• No randomized trials have reported results for pT2 and pT3a tumors.
• Studies show no clear advantage for adjuvant therapy in muscle-infiltrated tumors (pT2, pT3a).
• A trend toward improved survival suggests potential benefit for pT3b, pN+, and pT4 tumors, but this remains investigational.

Conclusions:

• Adjuvant chemotherapy following cystectomy or aggressive TUR for invasive bladder cancer is currently investigational.
• The benefit of adjuvant therapy has not been definitively proven.
• Patients should be encouraged to participate in well-designed clinical trials to clarify the role of chemotherapy.